Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMAHJEF)

Drug Name
Betamethasone Drug Info
Synonyms
betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate
Therapeutic ClassAntiinflammatory Agents
Cross-matching ID
PubChem CID
9782
ChEBI ID
CHEMBL632
CAS Number
CAS 378-44-9
TTD Drug ID
D0CW1P
VARIDT Drug ID
DR01392
ACDINA Drug ID
D00879

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Arginine and proline metabolism 2.04 1.67e-2 39/50 (78%) MAOA;MAOB;CNDP2;...
Valine, leucine and isoleucine degradation 1.98 8.34e-3 42/48 (87.5%) AOX1;ACAT1;PCCB;...
Histidine metabolism 1.94 1.11e-2 16/22 (72.73%) MAOA;MAOB;CNDP2;...
beta-Alanine metabolism 1.93 8.34e-3 25/30 (83.33%) CNDP2;ALDH9A1;ABAT;...
Tryptophan metabolism 1.83 2.17e-2 35/42 (83.33%) MAOA;AOX1;MAOB;...
Citrate cycle (TCA cycle) 1.82 1.81e-2 30/30 (100%) IDH2;DLAT;OGDHL;...
Glycolysis / Gluconeogenesis 1.76 2.98e-2 56/67 (83.58%) PGAM1;DLAT;ALDOB;...
Drug metabolism 1.73 4.38e-2 78/151 (51.66%) MAOA;AOX1;MAOB;...
Tyrosine metabolism 1.73 4.08e-2 30/36 (83.33%) MAOA;AOX1;MAOB;...
Glyoxylate and dicarboxylate metabolism 1.71 4.50e-2 23/30 (76.67%) GLUL;SHMT1;ACAT1;...
Propanoate metabolism 1.69 4.85e-2 30/34 (88.24%) ACAT1;PCCB;ABAT;...
Cell adhesion molecules -1.67 4.62e-2 118/148 (79.73%) CADM1;NECTIN3;ICAM1;...
Viral protein interaction with cytokine and cytokine re... -1.72 2.76e-2 84/100 (84%) CXCL6;CXCL12;IL10RA;...
Malaria -1.72 2.97e-2 44/50 (88%) GYPA;CD36;TGFB1;...
Other glycan degradation -1.73 2.84e-2 13/18 (72.22%) AGA;MAN2B2;FUCA1;...
Steroid hormone biosynthesis -1.73 2.79e-2 43/61 (70.49%) AKR1C4;CYP11B1;CYP3A7;...
Type I diabetes mellitus -1.74 2.84e-2 38/43 (88.37%) PTPRN;HLA-DPB1;HLA-E;...
TNF signaling pathway -1.74 2.90e-2 103/112 (91.96%) PIK3CD;MAPK9;IKBKB;...
SNARE interactions in vesicular transport -1.75 3.12e-2 19/33 (57.58%) STX11;STX18;SNAP23;...
Viral myocarditis -1.75 3.24e-2 53/60 (88.33%) LAMA2;HLA-DPB1;HLA-E;...
Influenza A -1.80 2.46e-2 156/172 (90.7%) TPSAB1;IFNAR2;TICAM1;...
Autoimmune thyroid disease -1.81 2.27e-2 46/53 (86.79%) HLA-DPB1;HLA-E;IL5;...
Allograft rejection -1.85 1.42e-2 32/38 (84.21%) HLA-DPB1;HLA-E;IL5;...
Rheumatoid arthritis -1.99 0.00e+0 78/93 (83.87%) TNFRSF11A;ATP6V1D;HLA-DPB1;...
Graft-versus-host disease -1.99 0.00e+0 32/42 (76.19%) KLRD1;HLA-DPA1;HLA-DRB1;...
Antigen processing and presentation -2.14 0.00e+0 60/78 (76.92%) IFI30;KLRD1;HLA-DPA1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 4uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H